Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as an injectable solution for intravenous and intravesical use. It is employed in the treatment of various solid tumours, including bladder, gastric, pancreatic and breast cancers, primarily in adult oncology patients.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Medac is used as a cytotoxic agent in several solid‑tumour indications.

- Bladder cancer (intravesical): provides local cytotoxic effect to reduce tumour recurrence. - Gastric cancer: contributes to tumour shrinkage as part of combination chemotherapy. - Pancreatic cancer: used in multi‑drug regimens to improve response rates. - Breast cancer: incorporated in systemic protocols for advanced disease. - Other solid tumours: applied where DNA cross‑linking agents are indicated.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during treatment. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: persistent tiredness reported by many patients. - Renal toxicity: transient changes in kidney function.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe hemorrhage: bleeding due to thrombocytopenia. - Hemolytic uremic syndrome: rare kidney and blood disorder. - Severe infection: opportunistic infections from immunosuppression.

Mitomycin requires careful monitoring and specific safety measures before, during and after administration.

- Baseline blood counts: obtain complete blood count prior to each cycle. - Renal function: assess serum creatinine and adjust dosing if impaired. - Pulmonary assessment: perform lung function tests for patients with pre‑existing lung disease. - Concomitant nephrotoxic drugs: avoid or monitor closely. - Pregnancy and lactation: contraindicated; discuss risks with women of child‑bearing potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - High‑dose cyclophosphamide: additive bone‑marrow suppression. - Nephrotoxic antibiotics (e.g., aminoglycosides): increased renal toxicity. - Anticoagulants: heightened risk of bleeding due to thrombocytopenia.

Moderate Interactions (Monitor Closely): - Other alkylating agents: cumulative myelosuppression. - NSAIDs: may worsen renal impairment. - CYP450 inducers or inhibitors: potential impact on metabolic activation.